QQQ   357.86 (-1.83%)
AAPL   173.93 (-0.89%)
MSFT   319.53 (-0.39%)
META   295.73 (-1.31%)
GOOGL   130.44 (-2.47%)
AMZN   129.33 (-4.41%)
TSLA   255.70 (-2.62%)
NVDA   410.17 (-2.89%)
NIO   8.46 (-4.19%)
BABA   84.12 (-1.89%)
AMD   96.11 (-4.22%)
T   15.31 (-1.61%)
F   12.20 (-1.30%)
MU   67.90 (-2.55%)
CGC   0.77 (-11.53%)
GE   112.97 (-1.64%)
DIS   82.73 (+0.21%)
AMC   7.71 (-5.51%)
PFE   32.85 (-2.29%)
PYPL   58.62 (-3.68%)
NFLX   384.15 (-0.56%)
QQQ   357.86 (-1.83%)
AAPL   173.93 (-0.89%)
MSFT   319.53 (-0.39%)
META   295.73 (-1.31%)
GOOGL   130.44 (-2.47%)
AMZN   129.33 (-4.41%)
TSLA   255.70 (-2.62%)
NVDA   410.17 (-2.89%)
NIO   8.46 (-4.19%)
BABA   84.12 (-1.89%)
AMD   96.11 (-4.22%)
T   15.31 (-1.61%)
F   12.20 (-1.30%)
MU   67.90 (-2.55%)
CGC   0.77 (-11.53%)
GE   112.97 (-1.64%)
DIS   82.73 (+0.21%)
AMC   7.71 (-5.51%)
PFE   32.85 (-2.29%)
PYPL   58.62 (-3.68%)
NFLX   384.15 (-0.56%)
QQQ   357.86 (-1.83%)
AAPL   173.93 (-0.89%)
MSFT   319.53 (-0.39%)
META   295.73 (-1.31%)
GOOGL   130.44 (-2.47%)
AMZN   129.33 (-4.41%)
TSLA   255.70 (-2.62%)
NVDA   410.17 (-2.89%)
NIO   8.46 (-4.19%)
BABA   84.12 (-1.89%)
AMD   96.11 (-4.22%)
T   15.31 (-1.61%)
F   12.20 (-1.30%)
MU   67.90 (-2.55%)
CGC   0.77 (-11.53%)
GE   112.97 (-1.64%)
DIS   82.73 (+0.21%)
AMC   7.71 (-5.51%)
PFE   32.85 (-2.29%)
PYPL   58.62 (-3.68%)
NFLX   384.15 (-0.56%)
QQQ   357.86 (-1.83%)
AAPL   173.93 (-0.89%)
MSFT   319.53 (-0.39%)
META   295.73 (-1.31%)
GOOGL   130.44 (-2.47%)
AMZN   129.33 (-4.41%)
TSLA   255.70 (-2.62%)
NVDA   410.17 (-2.89%)
NIO   8.46 (-4.19%)
BABA   84.12 (-1.89%)
AMD   96.11 (-4.22%)
T   15.31 (-1.61%)
F   12.20 (-1.30%)
MU   67.90 (-2.55%)
CGC   0.77 (-11.53%)
GE   112.97 (-1.64%)
DIS   82.73 (+0.21%)
AMC   7.71 (-5.51%)
PFE   32.85 (-2.29%)
PYPL   58.62 (-3.68%)
NFLX   384.15 (-0.56%)
NYSE:GLS

Gelesis (GLS) Stock Forecast, Price & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
Compare
Today's Range
N/A
50-Day Range
$0.11
▼
$0.33
52-Week Range
N/A
Volume
185,100 shs
Average Volume
386,034 shs
Market Capitalization
$11.63 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
ProfileEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media

GLS stock logo

About Gelesis (NYSE:GLS) Stock

Gelesis Holdings Inc., a commercial stage biotherapeutics company, developing a biomimicry to treat the genesis of obesity and GI-related chronic diseases. The company also provides PLENITY, an orally administered, non-stimulant, and non-systemic aid for weight management. In addition, it offers a product for obesity and overweight and a pipeline with potential therapies for non-alcoholic fatty liver disease/non-alcoholic steatohepatitis, type 2 diabetes, and GS500 for Functional Constipation. Gelesis Holdings Inc. was incorporated in 2006 and is headquartered in Boston, Massachusetts.


GLS Stock News Headlines

April 11, 2023 | msn.com
NYSE to suspend trading immediately in Gelesis Holdings
April 10, 2023 | finance.yahoo.com
NYSE to Suspend Trading Immediately in Gelesis Holdings, Inc. (GLS) and Commence Delisting Proceedings
September 21, 2023 | Behind the Markets (Ad)
BREAKING: Tiny biotech successfully treats blindness
There's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.
March 29, 2023 | msn.com
Looking Into Gelesis Holdings's Return On Capital Employed
March 28, 2023 | finance.yahoo.com
Gelesis Reports Fourth Quarter and Full Year 2022 Results
January 27, 2023 | seekingalpha.com
GLS Gelesis Holdings, Inc.
January 5, 2023 | finance.yahoo.com
Gelesis to Participate in the 25th Annual ICR Conference
January 4, 2023 | technews.tmcnet.com
NYSE to Suspend Trading Immediately in Warrants of Gelesis Holdings, Inc. (GLS WS) and Commence Delisting Proceedings
September 21, 2023 | Behind the Markets (Ad)
BREAKING: Tiny biotech successfully treats blindness
There's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.
November 21, 2022 | finance.yahoo.com
Gelesis Reports Upcoming Participation in Wolfe Research’s Annual Consumer Growth Conference
November 18, 2022 | finance.yahoo.com
Gelesis Receives Notice of NYSE Market Capitalization Listing Rule Non-Compliance
November 14, 2022 | seekingalpha.com
Gelesis Holdings, Inc. (GLS) Q3 2022 Earnings Call Transcript
November 14, 2022 | finance.yahoo.com
Gelesis Reports Third Quarter 2022 Results
November 7, 2022 | finance.yahoo.com
Gelesis to Report Third Quarter 2022 Financial Results on November 14, 2022
November 4, 2022 | finance.yahoo.com
Gelesis Receives Notice of NYSE Trading Share Price Listing Rule Non-Compliance
November 2, 2022 | finance.yahoo.com
Data Presented at Obesity Week Demonstrate that Gelesis Investigational Clinical-Stage Oral Superabsorbent Hydrogel Gel-B Preferentially Enhances the Growth of Akkermansia muciniphila in Preclinical Models Compared to Prebiotics
November 1, 2022 | finance.yahoo.com
Dr. Frank Greenway to Present Data from the LIGHT-UP Study with Gelesis’ Oral Hydrogel Treatment GS200 at Obesity Week
October 5, 2022 | ca.finance.yahoo.com
Investors in Gelesis Holdings (NYSE:GLS) have unfortunately lost 89% over the last year
September 9, 2022 | morningstar.com
Gelesis Holdings Inc GLS Stock Analysis
September 8, 2022 | finance.yahoo.com
Gelesis to Participate in the Jefferies Virtual Fitness & Wellness Summit
August 25, 2022 | finance.yahoo.com
Clinical Data from the LIGHT-UP Study Presented at the International Congress of Endocrinology Suggests New Gelesis Oral Hydrogel May Improve Insulin Sensitivity and Favorably Impact Metabolic Syndrome
August 24, 2022 | nasdaq.com
Investors one-year losses grow to 89% as the stock sheds US$21m this past week
August 17, 2022 | finance.yahoo.com
REPLAY: Fight Obesity With Biotech – Gelesis CEO, CFO in Fireside Chat
August 17, 2022 | msn.com
Analyzing Gelesis Holdings Short Interest
August 17, 2022 | finance.yahoo.com
Gelesis to Participate in Fireside Chat with IPO Edge Today at 2:00 PM ET
August 16, 2022 | finance.yahoo.com
Arming Consumers to Fight Obesity with Biotech – Join CEO and CFO of Gelesis in Fireside Chat Wednesday at 2 ET
August 15, 2022 | seekingalpha.com
Gelesis Holdings, Inc. (GLS) CEO Yishai Zohar on Q2 2022 Results - Earnings Call Transcript
See More Headlines
Receive GLS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Gelesis and its competitors with MarketBeat's FREE daily newsletter.

GLS Company Calendar

Today
9/21/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NYSE
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NYSE:GLS
CUSIP
N/A
CIK
1805087
Web
www.gelesis.com
Phone
N/A
Fax
N/A
Employees
2
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
($1.40)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-56,030,000.00
Net Margins
-221.38%
Pretax Margin
-214.62%
Return on Equity
N/A
Return on Assets
-14.98%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
0.30
Quick Ratio
0.21

Sales & Book Value

Annual Sales
$25.77 million
Price / Sales
0.00
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
($0.34) per share
Price / Book
N/A

Miscellaneous

Outstanding Shares
73,333,000
Free Float
64,606,000
Market Cap
$11.63 million
Optionable
Not Optionable
Beta
0.88
Metaverse Stocks And Why You Can't Ignore Them Cover
Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Key Executives

  • Mr. Yishai Zohar (Age 59)
    Founder, Pres, CEO & Director
    Comp: $689.95k
  • Mr. Elliot Maltz CPA (Age 37)
    CFO & Treasurer
    Comp: $486.26k
  • Dr. David Pass Pharm.D. (Age 53)
    COO & Chief Commercial Officer
  • Dr. Elaine Chiquette Pharm.D. (Age 55)
    Chief Scientific Officer
  • Ms. Joy Bauer M.S.
    MS, RDN, Chief Nutrition Officer of Plenity

Key Competitors

View All Competitors

Insiders

View All Insider Transactions













GLS Stock - Frequently Asked Questions

What is Gelesis' stock symbol?

Gelesis trades on the New York Stock Exchange (NYSE) under the ticker symbol "GLS."

How much money does Gelesis make?

Gelesis (NYSE:GLS) has a market capitalization of $0.00 and generates $25.77 million in revenue each year. The company earns $-56,030,000.00 in net income (profit) each year or ($1.40) on an earnings per share basis.

How can I contact Gelesis?

Gelesis' mailing address is 405 WEST 14TH STREET, AUSTIN TX, 78701. The official website for the company is www.gelesis.com. The company can be reached via email at 0.

This page (NYSE:GLS) was last updated on 9/21/2023 by MarketBeat.com Staff

My Account -